Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Retained Earnings (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Retained Earnings for 16 consecutive years, with -$510.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 4.2% to -$510.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$510.2 million, a 4.2% decrease, with the full-year FY2024 number at -$493.5 million, down 2.7% from a year prior.
  • Retained Earnings was -$510.2 million for Q3 2025 at Plus Therapeutics, down from -$505.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$436.2 million in Q1 2021 to a low of -$510.9 million in Q1 2025.
  • A 5-year average of -$474.3 million and a median of -$475.1 million in 2023 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: decreased 2.32% in 2021, then decreased 5.6% in 2025.
  • Plus Therapeutics' Retained Earnings stood at -$442.8 million in 2021, then dropped by 5.51% to -$467.2 million in 2022, then fell by 2.85% to -$480.5 million in 2023, then fell by 2.7% to -$493.5 million in 2024, then fell by 3.38% to -$510.2 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Retained Earnings are -$510.2 million (Q3 2025), -$505.7 million (Q2 2025), and -$510.9 million (Q1 2025).